Genprex, Inc. (GNPX)
GNPX Stock Price Chart
Explore Genprex, Inc. interactive price chart. Choose custom timeframes to analyze GNPX price movements and trends.
GNPX Company Profile
Discover essential business fundamentals and corporate details for Genprex, Inc. (GNPX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Mar 2018
Employees
15.00
Website
https://www.genprex.comCEO
Ryan M. Confer
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
GNPX Financial Timeline
Browse a chronological timeline of Genprex, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 14 Aug 2025
EPS came in at -$0.17 surpassing the estimated -$0.42 by +59.52%.
Earnings released on 12 May 2025
EPS came in at -$0.26 surpassing the estimated -$0.82 by +68.29%.
Earnings released on 7 Apr 2025
EPS came in at -$1.15 falling short of the estimated -$0.82 by -40.24%, while revenue for the quarter reached $9.92K .
Earnings released on 13 Nov 2024
EPS came in at -$1.23 falling short of the estimated -$1.13 by -8.85%.
Earnings released on 9 Aug 2024
EPS came in at -$3.00 falling short of the estimated -$2.30 by -30.43%.
Earnings released on 15 May 2024
EPS came in at -$3.69 falling short of the estimated -$2.54 by -45.28%.
Earnings released on 29 Mar 2024
EPS came in at -$3.96 falling short of the estimated -$3.93 by -0.76%, while revenue for the quarter reached $23.15K .
Stock split effective on 2 Feb 2024
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$5.20 falling short of the estimated -$0.11 by -4.63K%.
Earnings released on 21 Aug 2023
EPS came in at -$6.00 falling short of the estimated -$4.80 by -25.00%.
Earnings released on 22 May 2023
EPS came in at -$7.60 falling short of the estimated -$4.80 by -58.33%.
Earnings released on 31 Mar 2023
EPS came in at -$6.00 falling short of the estimated -$5.20 by -15.38%.
Earnings released on 14 Nov 2022
EPS came in at -$5.20 falling short of the estimated -$0.12 by -4.23K%.
Earnings released on 12 Aug 2022
EPS came in at -$4.40 falling short of the estimated -$4.00 by -10.00%.
Earnings released on 13 May 2022
EPS came in at -$4.80 falling short of the estimated -$3.60 by -33.33%.
Earnings released on 30 Mar 2022
EPS came in at -$4.80 falling short of the estimated -$0.09 by -5.23K%.
Earnings released on 15 Nov 2021
EPS came in at -$2.80 .
Earnings released on 13 Aug 2021
EPS came in at -$3.20 falling short of the estimated -$0.13 by -2.36K%.
Earnings released on 17 May 2021
EPS came in at -$5.60 falling short of the estimated -$0.12 by -4.57K%.
Earnings released on 26 Mar 2021
EPS came in at -$5.60 falling short of the estimated -$0.28 by -1.90K%.
Earnings released on 12 Nov 2020
EPS came in at -$2.80 falling short of the estimated -$0.21 by -1.23K%.
GNPX Stock Performance
Access detailed GNPX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.